The Progress in Dermatomyositis (ProDERM) study published in the New England Journal of Medicine reported a milestone in managing adult myositis. With the trial’s favorable results, adult myositis patients have new hope with the approval of Octagam® 10%.

“The ProDERM study will have a significant impact on clinical practice because IVIg is likely to become an important treatment option for patients with dermatomyositis,” said Rohit Aggarwal, M.D., MS, Medical Director of the Arthritis and Autoimmunity Center at the University of Pittsburgh School of Medicine and a member of the ProDERM study Steering Committee. “The study gives clinicians much more confidence in the efficacy and safety of intravenous immunoglobulin and provides valuable information about what type of patient is best suited for the treatment.”

We're aiming to host 20 DIY family fundraisers to celebrate this momentous 20th year combatting juvenile myositis.

Make it easy, fun, and fit your lifestyle.



Hear more about how you can get involved by watching this video. Join us in the fight to end JM!

Join other Cure JM families to help us deliver a proclamation of thanks to the Rare Disease Congressional Caucus for their critical research, drug discovery, and clinical trial breakthroughs in juvenile myositis. 

Let the Rare Disease Congressional Caucus know that the work they do for rare diseases matters to you and your family, and you want their continued support for better treatments and a cure!

Please sign and share!

Ask your family members and friends to sign to let our voices be heard.

Help us reach 1,000 signatures by March 17, 2023. 

The Cure JM National Family Conference is back, and registration is open!

Join us for three days with world-class JM researchers, engaging sessions for all, and social time to connect with new friends. The 14th Annual Cure JM National Family Conference is happening June 29 - July 2, 2023, at the Gaithersburg Marriott Washingtonian Center, just outside Washington, D.C.

We’re inviting all families affected by juvenile myositis. That means you’re invited! For the agenda and more details, click here.

Register now to secure your spot at the best rate. Early bird registration ends March 12th.

Use discount code: strongertogether

The Young Adult and Teen Get Together is an opportunity for any juvenile myositis patient aged 12+ to connect and get support from others on this JM journey.

The event will be lightly facilitated by Suzanne Edison, Cure JM's Mental Health Coordinator.

Let YOUR voice be heard! Patients aged 18-30 are invited to join the first-ever Advocates Council organizing meeting.

Our goal is to connect with each other to help move Cure JM’s mission forward in a collaborative environment. 

What is the Cure JM Advocates Council? We are a group of young adults coming together to discuss how we want to get involved in Cure JM's mission and let our voices be heard as new treatments and clinical trials are being planned.

To learn more about this program and how to join, click the button below.